Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 25c

Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q2 EPS of ($1.07), $0.25 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
• Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'